Literature DB >> 24608963

Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients.

T Liu1, G Li1, R Mu2, H Ye1, W Li3, Z Li1.   

Abstract

OBJECTIVE: The objective of this paper is to clarify the demographic, clinical and serologic characteristics of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) overlap syndrome, known as 'rhupus syndrome'.
METHODS: Between 1995 and 2012, 51 patients were classified as having rhupus among 3733 consecutive SLE patients. Rhupus was defined as a condition involving an overlap of RA and SLE features meeting the respective criteria of the American College of Rheumatology. The clinical and laboratory parameters of patients with rhupus syndrome were compared with those of 230 RA patients and 120 unselected SLE patients.
RESULTS: The age at the onset of rhupus was significantly younger than that of RA (p < 0.05), but similar to that of SLE. The initial manifestation was arthritis in 84.3% (43/51) of rhupus patients. Symptoms of SLE manifested after an average of 9.2 years. SLE was the initial diagnosis in 7.8% (four of 51) of patients, whereas both diseases developed simultaneously in 7.8% of the patients. SLE-associated manifestations were mild in rhupus syndrome, particularly neurologic disorders. Haematopoietic involvement was the most prominent systemic manifestation in rhupus patients.
CONCLUSION: Rhupus syndrome constitutes a subgroup of patients with distinct demographic, clinical and immunological characteristics. RA typically presents first, and less-severe SLE-associated damage is apparent.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Systemic lupus erythematosus; overlap; rheumatoid arthritis; rhupus

Mesh:

Year:  2014        PMID: 24608963     DOI: 10.1177/0961203314526439

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.

Authors:  Jing Li; Adam Csakai; Jialin Jin; Fengchun Zhang; Hang Yin
Journal:  ChemMedChem       Date:  2015-07-01       Impact factor: 3.466

2.  Rhupus; unusual presentations.

Authors:  Ora Shovman; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2015-05-28       Impact factor: 2.980

3.  [Clinical features of patients with Rhupus syndrome].

Authors:  Z F Li; X Wu; L J Wu; C N Luo; Y M Shi; Y Zhong; X M Chen; X Y Meng
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-18

4.  Primary Cutaneous Anaplastic Large Cell Lymphoma Arising in a Patient with Rhupus Syndrome and Sjogren's Syndrome.

Authors:  Zirui Gao; Qianxi Xu; Xue Chen; Dandan Mao; Jianzhong Zhang; Jiang Jin
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-30

5.  Rhupus syndrome and Chiari's network.

Authors:  Gokhan Sargin; Taskin Senturk; Songul Cildag
Journal:  J Family Med Prim Care       Date:  2018 Jan-Feb

6.  Need for Greater Attention to Joint Damage in Rhupus Patients: Results from an Ultrasound Study.

Authors:  Zhi-Xin Chen; Pei-Dan Yang; Min-Ying Liu; Ping-Fang Song; Qiang Xu
Journal:  Med Sci Monit       Date:  2020-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.